Not yet recruiting · NCT07428746

A study testing whether a GLP-1 medicine from Emory University, semaglutide, can lower blood sugar and help with weight.

Who can join: Adults 65+, women only, have type 2 diabetes, BMI 27+.
What you take: semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts: The full study runs about 2.6 years; your own time in it is usually shorter.
What you get: The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

Phase Phase 3Sponsor Emory UniversityDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 20

What this study is for

Full study title: Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes.

Primary condition: Diabetes Mellitus, Type 2.

Who can join, in detail

Age 65 and up

Sex Female

BMI 27 to 40

Key inclusion criteria

Postmenopausal women aged 65 years or older
Has type 2 diabetes
Body Mass Index (BMI) >=27 kg/m² to max 40kg/m2 (inclusive)
Hemoglobin A1c between 7-10% within 3 months of the first visit.
Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.

Key exclusion criteria

Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
eGFR <30 ml/min in the last 3 months
Patients with a history of treatment with anti-osteoporosis agents
Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
Documented presence of prosthesis or devices in the spine or hip

Where this study is enrolling

This trial has 1 US sites across 1 states. Contact the site coordinator directly to start the screening process.

Georgia

Grady Memorial Hospital
Atlanta, Georgia
Thaer Idrees, MD, FSSCI404-251-5357thaer.idrees@emory.edu

Follow this trial

We email you if NCT07428746 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: 2026-04. Expected completion: 2028-11. Last updated on ClinicalTrials.gov: 2026-02-24.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each program's public-facing page weekly.